Treatment-Resistant Depression: Oral Ketamine's Role

What STAT's Report Covers

A report published by STAT on July 27, 2026 looks at a question that comes up constantly in mental health care: what happens when standard oral antidepressants, like SSRIs or SNRIs, don't relieve someone's depression? STAT's headline frames this as a look at what's next for treatment-resistant depression (TRD), a term generally used when a person hasn't responded to two or more adequate trials of a standard antidepressant.

The source description available to us doesn't lay out every treatment option STAT discusses, so we won't guess at specifics beyond the headline. But the framing itself is significant. TRD affects a meaningful share of people who start on first-line antidepressants, and the search for what comes after has driven much of the recent interest in ketamine-based treatments, from IV infusions to esketamine nasal spray to compounded oral ketamine tablets and troches.

Why This Conversation Matters for Ketamine Tablet Readers

Coverage like this matters to our readers because it signals where the broader medical and media conversation is heading. When outlets like STAT, a publication that covers health, medicine, and the pharmaceutical industry closely, run a piece specifically about the gap between failed oral antidepressants and what patients should try next, it usually means clinicians and patients alike are asking that question more often. Ketamine, in its various forms, is one of the few options with a meaningful evidence base for rapid symptom relief in depression that hasn't responded to conventional treatment.

It's worth being precise about where oral ketamine tablets fit in that landscape. FDA-approved ketamine-based treatment for TRD currently means esketamine nasal spray (Spravato), used alongside an oral antidepressant under strict in-clinic monitoring. Oral ketamine tablets and troches, by contrast, are typically prescribed off-label, often through telehealth ketamine clinics or compounding pharmacies, and are not the same regulatory pathway as Spravato or IV ketamine administered in a clinical setting. That distinction matters when patients are comparing options after their oral antidepressants haven't worked.

Practical Considerations If You're Exploring Oral Ketamine After TRD

If you or someone you know has cycled through standard oral antidepressants without relief and is now researching ketamine as a next step, a few practical points are worth keeping in mind:

Understand the route-of-administration tradeoffs. Oral ketamine tablets undergo significant first-pass metabolism in the liver, converting a large portion of the dose into norketamine before it reaches systemic circulation. This generally means lower peak plasma levels and a slower onset compared with IV infusion or intranasal esketamine, though some patients report a smoother, more gradual experience as a result. Troches (lozenges dissolved under the tongue) sit somewhere in between, since sublingual absorption partially bypasses first-pass metabolism.

Ask about monitoring and follow-up. Because oral ketamine for depression is prescribed off-label, the level of clinical oversight varies widely between providers. Look for a prescriber who does an initial psychiatric evaluation, screens for contraindications like uncontrolled hypertension or a history of substance use disorder, and schedules follow-up check-ins to track both symptoms and side effects like dissociation, elevated blood pressure, or urinary symptoms with long-term use.

Treat it as one option among several, not a default. TRD treatment pathways discussed in pieces like STAT's typically include augmentation strategies (adding a second medication), switching antidepressant classes, transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) for severe cases, and ketamine or esketamine. Oral ketamine tablets can be a reasonable option for some patients, particularly those seeking a lower-intensity, at-home approach, but they're not automatically the right next step for everyone, and they work best as part of a broader plan that includes therapy and psychiatric follow-up rather than as a standalone fix.

Set realistic expectations on cost and access. Oral ketamine programs are often self-pay, since insurance coverage for off-label ketamine prescribing is inconsistent. Compare that against the copay and prior-authorization hurdles that can come with Spravato, which is FDA-approved but requires in-office administration and monitoring.

What to Watch Next

Pieces like STAT's are useful because they reflect how mainstream medical journalism is now treating ketamine-based options as a standard part of the TRD conversation rather than a fringe topic. For our readers, the takeaway isn't that oral tablets are better or worse than other ketamine routes, it's that the growing coverage makes it more important than ever to work with a qualified prescriber who can explain dosing, absorption, and monitoring specific to the oral route, and to keep an eye on how insurers, regulators, and researchers respond as demand for these treatments continues to rise in 2026.